92 related articles for article (PubMed ID: 24520579)
1. Micro-SPET/CT and histology results of zoledronate treatment in a nude mouse lung adenocarcinoma skeletal metastases model: a pilot study.
Zhang Y; Cheng D; Shi H; Tan H; Wu B; Gu Y; Li B
Hell J Nucl Med; 2013; 16(3):240-1. PubMed ID: 24520579
[No Abstract] [Full Text] [Related]
2. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
3. Reply to F. Valcamonico et al.
Smith MR; Halabi S; Small EJ
J Clin Oncol; 2014 Nov; 32(32):3685. PubMed ID: 25225438
[No Abstract] [Full Text] [Related]
4. Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
Kimura T; Egawa S
Eur Urol; 2016 Apr; 69(4):754-5. PubMed ID: 26972498
[No Abstract] [Full Text] [Related]
5. Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
Valcamonico F; Petrelli F; Ferrari L; Ferrari V; Grisanti S; Barni S; Berruti A
J Clin Oncol; 2014 Nov; 32(32):3684-5. PubMed ID: 25225432
[No Abstract] [Full Text] [Related]
6. Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
Cappetta A; Spano L; Evangelista L; Zovato S; Opocher G; Pastorelli D
Anticancer Drugs; 2015 Feb; 26(2):232-5. PubMed ID: 25243456
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
Ko CH; Yue GG; Gao S; Luo KW; Siu WS; Shum WT; Shiu HT; Lee JK; Li G; Leung PC; Evdokiou A; Lau CB
J Ethnopharmacol; 2017 May; 204():77-85. PubMed ID: 28412218
[TBL] [Abstract][Full Text] [Related]
8. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yonese J; Fukui I
Int J Urol; 2008 Jun; 15(6):546-7. PubMed ID: 18489646
[TBL] [Abstract][Full Text] [Related]
9. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
10. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
11. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Pouessel D; Culine S
Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
13. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Smith A; Kressley A; Saif MW
JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
[No Abstract] [Full Text] [Related]
14. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
15. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of a congenital urine bladder diverticulum by 99mTc-MDP SPET/CT scan in a female with bone metastases.
Meng Z; Tan J; Dong F; Jia Q; Zhang F
Hell J Nucl Med; 2009; 12(3):276-8. PubMed ID: 19936344
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Mystakidou K; Katsouda E; Parpa E; Vlahos L
J Pain Palliat Care Pharmacother; 2005; 19(3):41-5. PubMed ID: 16219610
[TBL] [Abstract][Full Text] [Related]
18. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
19. The use of zoledronic acid in pediatric cancer patients.
August KJ; Dalton A; Katzenstein HM; George B; Olson TA; Wasilewski-Masker K; Rapkin LB
Pediatr Blood Cancer; 2011 Apr; 56(4):610-4. PubMed ID: 21298747
[TBL] [Abstract][Full Text] [Related]
20. Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tu SM; Chen AH
Can J Urol; 2012 Jun; 19(3):6268. PubMed ID: 22704311
[No Abstract] [Full Text] [Related]
[Next] [New Search]
